APO Research
Talk to an analyst

APO RESEARCH · REPORT

LFA-based Cardiac

Lateral Flow Assay is a simple to use diagnostic device used to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals, or contaminants in water supplies, foodstuffs, or animal feeds.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Lateral Flow Assay is a simple to use diagnostic device used to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals, or contaminants in water supplies, foodstuffs, or animal feeds.

Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart. These biomarkers are used to diagnose heart functioning, risk stratifications, and cardiac diseases in patients. Biomarker is a quantifiable and measurable biological parameter that includes an enzyme, hormones, and proteins, all associated with heart function, failure, or damage.

Selected research

Market Outlook & Growth Opportunities

Global LFA-based Cardiac Market Outlook and Growth Opportunities 2026

28 December 2025196 pages

Choose your research edition.

Industry ResearchLFA-based Cardiac Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal LFA-based Cardiac Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal LFA-based Cardiac Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal LFA-based Cardiac Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal LFA-based Cardiac Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

Lateral Flow Assay is a simple to use diagnostic device used to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals, or contaminants in water supplies, foodstuffs, or animal feeds.

Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart. These biomarkers are used to diagnose heart functioning, risk stratifications, and cardiac diseases in patients. Biomarker is a quantifiable and measurable biological parameter that includes an enzyme, hormones, and proteins, all associated with heart function, failure, or damage.

The industry's leading producers are Roche, Abbott and Siemens, with revenues of 26.24%, 16.11% and 11.04% respectively in 2019.

Read the full market overview

This report provides an overview of the global LFA-based Cardiac market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of LFA-based Cardiac and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents LFA-based Cardiac revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global LFA-based Cardiac market.

LFA-based Cardiac Segment by Company

Roche

Abbott

Siemens

Danaher

Bio-Rad Laboratories

BioMérieux

Thermo Fisher

Ortho Clinical Diagnostics

LSI Medience Corporation

Randox laboratories

Wondfo Biotech

LFA-based Cardiac Segment by Type

Troponin I

Troponin T

CK-MB

Myoglobin

Others

LFA-based Cardiac Segment by Application

Laboratory Testing

Point-of-care Testing

LFA-based Cardiac Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global LFA-based Cardiac status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the LFA-based Cardiac key companies, revenue, market share, and recent developments.

3. To split the LFA-based Cardiac breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions LFA-based Cardiac market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify LFA-based Cardiac significant trends, drivers, influence factors in global and regions.

6. To analyze LFA-based Cardiac competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global LFA-based Cardiac market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of LFA-based Cardiac and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of LFA-based Cardiac.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global LFA-based Cardiac industry.

Chapter 3: Detailed analysis of LFA-based Cardiac company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of LFA-based Cardiac in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of LFA-based Cardiac in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. LFA-based Cardiac Industry Trends Table 2. LFA-based Cardiac Industry Drivers Table 3. LFA-based Cardiac Industry Opportunities and Challenges Table 4. LFA-based Cardiac Industry Restraints Table 5. Global LFA-based Cardiac Revenue by Company (US$ Million) & (2021-2026) Table 6. Global LFA-based Cardiac Revenue Share by Company (2021-2026) Table 7. Global LFA-based Cardiac Company Ranking, (2024-2026) & (US$ Million) Table 8. Global LFA-based Cardiac Key Company Manufacturing Base & Headquarters Table 9. Global LFA-based Cardiac Company, Product Type & Application Table 10. Global LFA-based Cardiac Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global LFA-based Cardiac by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Troponin I Table 15. Significant Companies of Troponin T Table 16. Significant Companies of CK-MB Table 17. Significant Companies of Myoglobin Table 18. Significant Companies of Others Table 19. Global LFA-based Cardiac Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global LFA-based Cardiac Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global LFA-based Cardiac Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global LFA-based Cardiac Sales Value Share by Type (2021-2026) Table 23. Global LFA-based Cardiac Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Laboratory Testing Table 25. Significant Companies of Point-of-care Testing Table 26. Global LFA-based Cardiac Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global LFA-based Cardiac Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global LFA-based Cardiac Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global LFA-based Cardiac Sales Value Share by Application (2021-2026) Table 30. Global LFA-based Cardiac Sales Value Share by Application (2027-2032) Table 31. Global LFA-based Cardiac Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global LFA-based Cardiac Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global LFA-based Cardiac Sales Value Share by Region (2021-2026) Table 34. Global LFA-based Cardiac Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global LFA-based Cardiac Sales Value Share by Region (2027-2032) Table 36. Global LFA-based Cardiac Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global LFA-based Cardiac Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global LFA-based Cardiac Sales Value Market Share by Country (2021-2026) Table 39. Global LFA-based Cardiac Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global LFA-based Cardiac Sales Value Market Share by Country (2027-2032) Table 41. Roche Company Information Table 42. Roche Business Overview Table 43. Roche LFA-based Cardiac Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Roche LFA-based Cardiac Product Portfolio Table 45. Roche Recent Development Table 46. Abbott Company Information Table 47. Abbott Business Overview Table 48. Abbott LFA-based Cardiac Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Abbott LFA-based Cardiac Product Portfolio Table 50. Abbott Recent Development Table 51. Siemens Company Information Table 52. Siemens Business Overview Table 53. Siemens LFA-based Cardiac Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Siemens LFA-based Cardiac Product Portfolio Table 55. Siemens Recent Development Table 56. Danaher Company Information Table 57. Danaher Business Overview Table 58. Danaher LFA-based Cardiac Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Danaher LFA-based Cardiac Product Portfolio Table 60. Danaher Recent Development Table 61. Bio-Rad Laboratories Company Information Table 62. Bio-Rad Laboratories Business Overview Table 63. Bio-Rad Laboratories LFA-based Cardiac Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Bio-Rad Laboratories LFA-based Cardiac Product Portfolio Table 65. Bio-Rad Laboratories Recent Development Table 66. BioMérieux Company Information Table 67. BioMérieux Business Overview Table 68. BioMérieux LFA-based Cardiac Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. BioMérieux LFA-based Cardiac Product Portfolio Table 70. BioMérieux Recent Development Table 71. Thermo Fisher Company Information Table 72. Thermo Fisher Business Overview Table 73. Thermo Fisher LFA-based Cardiac Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Thermo Fisher LFA-based Cardiac Product Portfolio Table 75. Thermo Fisher Recent Development Table 76. Ortho Clinical Diagnostics Company Information Table 77. Ortho Clinical Diagnostics Business Overview Table 78. Ortho Clinical Diagnostics LFA-based Cardiac Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Ortho Clinical Diagnostics LFA-based Cardiac Product Portfolio Table 80. Ortho Clinical Diagnostics Recent Development Table 81. LSI Medience Corporation Company Information Table 82. LSI Medience Corporation Business Overview Table 83. LSI Medience Corporation LFA-based Cardiac Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. LSI Medience Corporation LFA-based Cardiac Product Portfolio Table 85. LSI Medience Corporation Recent Development Table 86. Randox laboratories Company Information Table 87. Randox laboratories Business Overview Table 88. Randox laboratories LFA-based Cardiac Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Randox laboratories LFA-based Cardiac Product Portfolio Table 90. Randox laboratories Recent Development Table 91. Wondfo Biotech Company Information Table 92. Wondfo Biotech Business Overview Table 93. Wondfo Biotech LFA-based Cardiac Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 94. Wondfo Biotech LFA-based Cardiac Product Portfolio Table 95. Wondfo Biotech Recent Development Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. LFA-based Cardiac Product Image Figure 2. Global LFA-based Cardiac Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global LFA-based Cardiac Market Size (2021-2032) & (US$ Million) Figure 4. Global LFA-based Cardiac Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Troponin I Image Figure 8. Troponin T Image Figure 9. CK-MB Image Figure 10. Myoglobin Image Figure 11. Others Image Figure 12. Global LFA-based Cardiac Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global LFA-based Cardiac Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global LFA-based Cardiac Sales Value Share by Type (2021-2032) Figure 15. Laboratory Testing Image Figure 16. Point-of-care Testing Image Figure 17. Global LFA-based Cardiac Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global LFA-based Cardiac Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global LFA-based Cardiac Sales Value Share by Application (2021-2032) Figure 20. Global LFA-based Cardiac Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global LFA-based Cardiac Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America LFA-based Cardiac Sales Value (2021-2032) & (US$ Million) Figure 23. North America LFA-based Cardiac Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe LFA-based Cardiac Sales Value (2021-2032) & (US$ Million) Figure 25. Europe LFA-based Cardiac Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific LFA-based Cardiac Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific LFA-based Cardiac Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America LFA-based Cardiac Sales Value (2021-2032) & (US$ Million) Figure 29. South America LFA-based Cardiac Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa LFA-based Cardiac Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa LFA-based Cardiac Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt LFA-based Cardiac Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Troponin I
  • Troponin T
  • CK-MB
  • Myoglobin
  • Others
Applications
  • Laboratory Testing
  • Point-of-care Testing
Companies covered
  • Roche
  • Abbott
  • Siemens
  • Danaher
  • Bio-Rad Laboratories
  • BioMérieux
  • Thermo Fisher
  • Ortho Clinical Diagnostics
  • LSI Medience Corporation
  • Randox laboratories
  • Wondfo Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global LFA-based Cardiac Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global LFA-based Cardiac Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 LFA-based Cardiac Market Dynamics
  1. 2.1 LFA-based Cardiac Industry Trends
  2. 2.2 LFA-based Cardiac Industry Drivers
  3. 2.3 LFA-based Cardiac Industry Opportunities and Challenges
  4. 2.4 LFA-based Cardiac Industry Restraints
3 LFA-based Cardiac Market by Company
  1. 3.1 Global LFA-based Cardiac Company Revenue Ranking in 2025
  2. 3.2 Global LFA-based Cardiac Revenue by Company (2021-2026)
  3. 3.3 Global LFA-based Cardiac Company Ranking (2024-2026)
  4. 3.4 Global LFA-based Cardiac Company Manufacturing Base and Headquarters
  5. 3.5 Global LFA-based Cardiac Company Product Type and Application
  6. 3.6 Global LFA-based Cardiac Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global LFA-based Cardiac Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 LFA-based Cardiac Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 LFA-based Cardiac Market by Type
  1. 4.1 LFA-based Cardiac Type Introduction
  2. 4.1.1 Troponin I
  3. 4.1.2 Troponin T
  4. 4.1.3 CK-MB
  5. 4.1.4 Myoglobin
  6. 4.1.5 Others
  7. 4.2 Global LFA-based Cardiac Sales Value by Type
  8. 4.2.1 Global LFA-based Cardiac Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global LFA-based Cardiac Sales Value by Type (2021-2032)
  10. 4.2.3 Global LFA-based Cardiac Sales Value Share by Type (2021-2032)
5 LFA-based Cardiac Market by Application
  1. 5.1 LFA-based Cardiac Application Introduction
  2. 5.1.1 Laboratory Testing
  3. 5.1.2 Point-of-care Testing
  4. 5.2 Global LFA-based Cardiac Sales Value by Application
  5. 5.2.1 Global LFA-based Cardiac Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global LFA-based Cardiac Sales Value by Application (2021-2032)
  7. 5.2.3 Global LFA-based Cardiac Sales Value Share by Application (2021-2032)
6 LFA-based Cardiac Regional Value Analysis
  1. 6.1 Global LFA-based Cardiac Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global LFA-based Cardiac Sales Value by Region (2021-2032)
  3. 6.2.1 Global LFA-based Cardiac Sales Value by Region: 2021-2026
  4. 6.2.2 Global LFA-based Cardiac Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America LFA-based Cardiac Sales Value (2021-2032)
  7. 6.3.2 North America LFA-based Cardiac Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe LFA-based Cardiac Sales Value (2021-2032)
  10. 6.4.2 Europe LFA-based Cardiac Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific LFA-based Cardiac Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific LFA-based Cardiac Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America LFA-based Cardiac Sales Value (2021-2032)
  16. 6.6.2 South America LFA-based Cardiac Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa LFA-based Cardiac Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa LFA-based Cardiac Sales Value Share by Country, 2025 VS 2032
7 LFA-based Cardiac Country-level Value Analysis
  1. 7.1 Global LFA-based Cardiac Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global LFA-based Cardiac Sales Value by Country (2021-2032)
  3. 7.2.1 Global LFA-based Cardiac Sales Value by Country (2021-2026)
  4. 7.2.2 Global LFA-based Cardiac Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt LFA-based Cardiac Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt LFA-based Cardiac Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt LFA-based Cardiac Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche
  2. 8.1.1 Roche Company Information
  3. 8.1.2 Roche Business Overview
  4. 8.1.3 Roche LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Roche LFA-based Cardiac Product Portfolio
  6. 8.1.5 Roche Recent Developments
  7. 8.2 Abbott
  8. 8.2.1 Abbott Company Information
  9. 8.2.2 Abbott Business Overview
  10. 8.2.3 Abbott LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Abbott LFA-based Cardiac Product Portfolio
  12. 8.2.5 Abbott Recent Developments
  13. 8.3 Siemens
  14. 8.3.1 Siemens Company Information
  15. 8.3.2 Siemens Business Overview
  16. 8.3.3 Siemens LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Siemens LFA-based Cardiac Product Portfolio
  18. 8.3.5 Siemens Recent Developments
  19. 8.4 Danaher
  20. 8.4.1 Danaher Company Information
  21. 8.4.2 Danaher Business Overview
  22. 8.4.3 Danaher LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Danaher LFA-based Cardiac Product Portfolio
  24. 8.4.5 Danaher Recent Developments
  25. 8.5 Bio-Rad Laboratories
  26. 8.5.1 Bio-Rad Laboratories Company Information
  27. 8.5.2 Bio-Rad Laboratories Business Overview
  28. 8.5.3 Bio-Rad Laboratories LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bio-Rad Laboratories LFA-based Cardiac Product Portfolio
  30. 8.5.5 Bio-Rad Laboratories Recent Developments
  31. 8.6 BioMérieux
  32. 8.6.1 BioMérieux Company Information
  33. 8.6.2 BioMérieux Business Overview
  34. 8.6.3 BioMérieux LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  35. 8.6.4 BioMérieux LFA-based Cardiac Product Portfolio
  36. 8.6.5 BioMérieux Recent Developments
  37. 8.7 Thermo Fisher
  38. 8.7.1 Thermo Fisher Company Information
  39. 8.7.2 Thermo Fisher Business Overview
  40. 8.7.3 Thermo Fisher LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Thermo Fisher LFA-based Cardiac Product Portfolio
  42. 8.7.5 Thermo Fisher Recent Developments
  43. 8.8 Ortho Clinical Diagnostics
  44. 8.8.1 Ortho Clinical Diagnostics Company Information
  45. 8.8.2 Ortho Clinical Diagnostics Business Overview
  46. 8.8.3 Ortho Clinical Diagnostics LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Ortho Clinical Diagnostics LFA-based Cardiac Product Portfolio
  48. 8.8.5 Ortho Clinical Diagnostics Recent Developments
  49. 8.9 LSI Medience Corporation
  50. 8.9.1 LSI Medience Corporation Company Information
  51. 8.9.2 LSI Medience Corporation Business Overview
  52. 8.9.3 LSI Medience Corporation LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  53. 8.9.4 LSI Medience Corporation LFA-based Cardiac Product Portfolio
  54. 8.9.5 LSI Medience Corporation Recent Developments
  55. 8.10 Randox laboratories
  56. 8.10.1 Randox laboratories Company Information
  57. 8.10.2 Randox laboratories Business Overview
  58. 8.10.3 Randox laboratories LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Randox laboratories LFA-based Cardiac Product Portfolio
  60. 8.10.5 Randox laboratories Recent Developments
  61. 8.11 Wondfo Biotech
  62. 8.11.1 Wondfo Biotech Company Information
  63. 8.11.2 Wondfo Biotech Business Overview
  64. 8.11.3 Wondfo Biotech LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Wondfo Biotech LFA-based Cardiac Product Portfolio
  66. 8.11.5 Wondfo Biotech Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst